Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Eriksson

Showing results (21-30 of 58) with videos related to

Pageof 6
Sort By:
Neuropsychiatric Disease and Treatment|February 11, 2014
A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorderGang Wang, Alexander McIntyre, Willie R Earley, et al.
Plos One|January 2, 2025
The Scania Accelerated Intermittent Theta-burst Implementation Study (SATIS)-Lessons from an accelerated treatment protocolMarcus Persson, Viktor Fabri, Alexander Reijbrandt, et al.
Journal of Interprofessional Care|August 11, 2021
Team-based visits within Swedish child healthcare services: a national cross-sectional studyUlrika Svea Nygren, Ylva Tindberg, Leif Eriksson, et al.
Journal of Comparative Effectiveness Research|October 3, 2014
Impact of extended-release quetiapine fumarate on hospitalization length and cost in schizophrenia and bipolar disorder patients: a retrospective, hospital-based, US-cohort analysisJulie C Locklear, Peter Wahlqvist, Urban Gustafsson, et al.
Human Psychopharmacology|December 7, 2011
Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studiesDan J Stein, Borwin Bandelow, Charles Merideth, et al.
Depression and Anxiety|August 25, 2010
Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trialMichael Liebowitz, Raymond W Lam, Ulla Lepola, et al.
Journal of Clinical Psychopharmacology|December 17, 2014
Safety and tolerability of dexmecamylamine (TC-5214) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to antidepressant therapy: results of a long-term studyRaj Tummala, Dhaval Desai, Johan Szamosi, et al.
Depression and Anxiety|July 4, 2012
Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depressionMichael E Thase, Koen Demyttenaere, Willie R Earley, et al.
International Clinical Psychopharmacology|October 29, 2013
Efficacy of extended release quetiapine fumarate monotherapy in elderly patients with major depressive disorder: secondary analyses in subgroups of patients according to baseline anxiety, sleep disturbance, and pain levelsStuart A Montgomery, A Carlo Altamura, Heikki Katila, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|April 10, 2013
Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorderHeikki Katila, Irina Mezhebovsky, Amy Mulroy, et al.
Pageof 6

Showing results (21-30 of 58) with videos related to

Sort By:
Pageof 6
Neuropsychiatric Disease and Treatment|February 11, 2014
A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorderGang Wang, Alexander McIntyre, Willie R Earley, et al.
Plos One|January 2, 2025
The Scania Accelerated Intermittent Theta-burst Implementation Study (SATIS)-Lessons from an accelerated treatment protocolMarcus Persson, Viktor Fabri, Alexander Reijbrandt, et al.
Journal of Interprofessional Care|August 11, 2021
Team-based visits within Swedish child healthcare services: a national cross-sectional studyUlrika Svea Nygren, Ylva Tindberg, Leif Eriksson, et al.
Journal of Comparative Effectiveness Research|October 3, 2014
Impact of extended-release quetiapine fumarate on hospitalization length and cost in schizophrenia and bipolar disorder patients: a retrospective, hospital-based, US-cohort analysisJulie C Locklear, Peter Wahlqvist, Urban Gustafsson, et al.
Human Psychopharmacology|December 7, 2011
Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studiesDan J Stein, Borwin Bandelow, Charles Merideth, et al.
Depression and Anxiety|August 25, 2010
Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trialMichael Liebowitz, Raymond W Lam, Ulla Lepola, et al.
Journal of Clinical Psychopharmacology|December 17, 2014
Safety and tolerability of dexmecamylamine (TC-5214) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to antidepressant therapy: results of a long-term studyRaj Tummala, Dhaval Desai, Johan Szamosi, et al.
Depression and Anxiety|July 4, 2012
Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depressionMichael E Thase, Koen Demyttenaere, Willie R Earley, et al.
International Clinical Psychopharmacology|October 29, 2013
Efficacy of extended release quetiapine fumarate monotherapy in elderly patients with major depressive disorder: secondary analyses in subgroups of patients according to baseline anxiety, sleep disturbance, and pain levelsStuart A Montgomery, A Carlo Altamura, Heikki Katila, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|April 10, 2013
Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorderHeikki Katila, Irina Mezhebovsky, Amy Mulroy, et al.
Pageof 6